Press releases

Company's new lead system reduces implant size of the world's smallest and thinnest high-energy devices

Authors identify important differences between drug-eluting stent brands

Highlights of the week's events include late-breaking trial presentations from the MADIT II clinical trial and the ALTITUDE Clinical Science Program

Data from landmark trial provide important insight for physicians in treating heart attack patients

A live webcast and replay of the May 12 conference session will be available. Learn how to tune in.

We're off to a good start on the year," said Jim Tobin, President and Chief Executive Officer

Boston Scientific today announced special items that will reduce its GAAP earnings for the first quarter

Company will webcast its April 21 call. Learn how to tune in.

Upheld District Court's decision that JNJ's Bx Velocity and Cypher Stent Systems infringe Boston Scientific's patent

Legislation will help evaluate the current state of chronic pain care in the United States

Three-year results and two-year pooled analysis presented at ACC demonstrate continued positive outcomes for both PROMUS® and TAXUS® Stents

Analysis of economic and quality of life outcomes are based on one-year data from landmark SYNTAX trial

Presentations to include additional analyses of one-year data from the landmark SYNTAX study

Upgrade follows the Moody's actions of March 12, when it raised Company's outlook to stable from negative

iCross™ designed to improve the deliverability of Company's market-leading intravascular ultrasound (IVUS) technology

Rating agency notes that Company has been able to retain market share in the DES arena while rebuilding its CRM presence with new product launches

A live webcast of the March 17 conference session will be available.

Legislation to evaluate the current state of chronic pain care will now move to consideration by the full House

Japanese patients now have access to second-generation drug-eluting stent

Joel Fleishman to retire from Board

Adjustments reflected in the Company's Form 10-K to be filed tomorrow

Data show comparable safety for complex patients treated with TAXUS® Express2™ Stents and bypass surgery

Journal of American College of Cardiology publishes positive ATLAS clinical data

PLATINUM clinical program to evaluate PROMUS™ Element™ Platinum Chromium Stent

Q4 adjusted results in line with expectations; Company well positioned for 2009 and beyond

Product is Japan's first second-generation drug-eluting stent

Agreement stops all litigation in interventional cardiology and endovascular repair

Provides Company the opportunity to supply therapies for VA patients at risk of sudden cardiac death and bradycardia arrhythmias

Court found patent to be invalid as obvious over the prior art; Company considering its options for challenging the decision

Company will webcast its January 29 conference call

A live webcast of the January 14 presentation will be available

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology

First patient enrolled in Carotid WALLSTENT® Endoprosthesis registry

First low-profile, pre-mounted stent approved specifically for use in renal arteries

A live webcast of the December 2, 2008 session will be available

New design provides more options for treating patients with complex lesions

Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service...

Confirms clinical value and cost-effectiveness of spinal cord stimulation

Leading carotid stent in Europe and other international markets now available in the United States

"For the second consecutive quarter, we maintained our strong U.S. DES market share leadership," said President and CEO Jim Tobin

Landmark trial provides new insight for physicians

Outcomes from the study of 22,000 patients with coronary artery disease continues to show impressive safety and efficacy data

New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients

Company moves up Q3 earnings release date

TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts

Joint efforts will focus on intravascular ultrasound (IVUS)

Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...

Two-year pooled ARRIVE data showed the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes

New coronary stent features thin struts designed for more uniform drug delivery

TAXUS Liberte drug eluting stent, launched in Europe and other international markets in 2005, to launch in U.S. next month